Skip to main content

Recurrent Pericarditis

0
Pipeline Programs
1
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Kiniksa Pharmaceuticals
4 programs
REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult PatientsN/A1 trial
KPL-387PHASE_21 trial
KPL-914PHASE_21 trial
RilonaceptPHASE_31 trial
Active Trials
NCT04687358Active Not Recruiting500Est. Mar 2029
NCT07288216Recruiting80Est. Dec 2029
NCT03980522Completed26Est. May 2019
+1 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Kiniksa PharmaceuticalsRilonacept
Kiniksa PharmaceuticalsKPL-387
Kiniksa PharmaceuticalsKPL-914
Kiniksa PharmaceuticalsREgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients

Clinical Trials (4)

Total enrollment: 692 patients across 4 trials

NCT03737110Kiniksa PharmaceuticalsRilonacept

Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis

Start: Jan 2019Est. completion: Jun 202286 patients
Phase 3Completed
NCT07288216Kiniksa PharmaceuticalsKPL-387

Transition to KPL-387 Monotherapy Dosing & Administration Study

Start: Mar 2026Est. completion: Dec 202980 patients
Phase 2Recruiting
NCT03980522Kiniksa PharmaceuticalsKPL-914

A Pilot Study of KPL-914 in Recurrent Pericarditis

Start: Jan 2018Est. completion: May 201926 patients
Phase 2Completed
NCT04687358Kiniksa PharmaceuticalsREgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients

REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients

Start: Mar 2021Est. completion: Mar 2029500 patients
N/AActive Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 692 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.